


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on March 8, 2004

Eric T. Addington	52,403
Name of Attorney/Agent	Registration No.
	
Signature of Attorney or Agent	



P&G Case CM2569CQ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
Ekaterina Ponomarenko et al. : Confirmation No.  
Serial No. 10/730,659 : Group Art Unit  
Filed December 8, 2003 : Examiner

For Cellulose Fibers Comprising Radiation Activatable Resin Formalities

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☒ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☒ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_, filed \_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR


☐ (4) Copies of all said documents, except Cite Numbers \_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By   
Eric T. Addington  
Attorney for Applicant(s)  
Registration No. 52,403  
(513) 626-1602

Date: March 8, 2004  
Customer No. 27752  
(IDS.doc) (Last Revised 10/10/03)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <p style="text-align: center; font-size: 1.2em; font-weight: bold;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p> <p style="text-align: center;">SHEET 1 of 2</p>	<p style="text-align: center; font-weight: bold;">COMPLETE IF KNOWN</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/730,659</td> </tr> <tr> <td>Confirmation Number</td> <td></td> </tr> <tr> <td>Filing Date</td> <td>December 8, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Ekaterina Ponomarenko</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>CM2569CQ</td> </tr> </table>	Application Number	10/730,659	Confirmation Number		Filing Date	December 8, 2003	First Named Inventor	Ekaterina Ponomarenko	Group Art Unit		Examiner Name		Attorney Docket Number	CM2569CQ
Application Number	10/730,659														
Confirmation Number															
Filing Date	December 8, 2003														
First Named Inventor	Ekaterina Ponomarenko														
Group Art Unit															
Examiner Name															
Attorney Docket Number	CM2569CQ														



### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-3,224,926	12-21-1965	Bernardin	
		US-3,241,533	03-22-1966	Balmer	
		US-3,440,135	04-22-1969	Chung	
		US-3,658,613	04-25-1972	Steiger	
		US-3,756,913	09-04-1973	Wodka	
		US-3,819,470	06-25-1974	Shaw et al.	
		US-3,932,209	01-13-1976	Chatterjee	
		US-3,987,968	10-26-1976	Moore et al.	
		US-4,035,147	07-12-1977	Sangenis et al.	
		US-4,689,118	08-25-1987	Makoui et al.	
		US-4,737,559	04-12-1988	Kellen et al.	
		US-4,748,044	05-31-1988	Fottinger et al.	
		US-4,822,453	04-18-1989	Dean et al.	
		US-4,853,086	08-01-1989	Graef	
		US-4,889,595	12-26-1989	Herron et al.	
		US-4,935,022	06-19-1990	Lash et al.	
		US-5,026,806	06-25-1991	Rehmer et al.	
		US-5,137,537	08-11-1992	Herron et al.	
		US-5,183,707	02-02-1993	Herron et al.	
		US-5,190,563	03-02-1993	Herron et al.	
		US-5,549,791	08-27-1996	Herron et al.	
		US-5,587,261	12-24-1996	Audett et al.	
		US-5,998,511	12-07-1999	Westland et al.	
		US-6,090,236	07-18-1990	Nohr et al.	
		US-6,184,271	02-06-2001	Westland et al.	
		US-			

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		EP 0 427 316 A2	05-15-1991	The Procter & Gamble Cellulose Company		
		EP 0 705 365 B1	04-10-1996	Stora Kopparbergs Bergslags Aktiebolag		
		JP 1995-96561	10-18-1995	Shin Etsu Chem. Co. Ltd.		
		JP 1996-006252 A	01-12-1996	Sony Corporation		
		WO 98/27262 A1	06-25-1998	Weyerhaeuser Company		
		WO 99/30843 A1	06-24-1999	Steris Corporation		
		WO 99/45879 A1	09-16-1999	The Procter & Gamble Co.		
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**